Last reviewed · How we verify
Nexvax2
At a glance
| Generic name | Nexvax2 |
|---|---|
| Sponsor | ImmusanT, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD) (PHASE2)
- Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease (PHASE1)
- Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease (PHASE1)
- Safety Study of Nexvax2 in Subjects With Coeliac Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nexvax2 CI brief — competitive landscape report
- Nexvax2 updates RSS · CI watch RSS
- ImmusanT, Inc. portfolio CI